

Success of the IPO of SuperSonic Imagine on Euronext in Paris, raising €50m

April 9th, 2014 - SuperSonic Imagine (the "Company"), announces the success of its initial public offering on the regulated market of Euronext in Paris.

Jacques Souquet, Founder and Chief Executive Officer of the SuperSonic Imagine, stated: *"We are delighted with the success of our IPO on Euronext Paris, which has enabled us to raise substantial funds. This operation will allow us to accelerate our geographical and commercial expansion and maximize the technological potential of Aixplorer. SuperSonic Imagine's Initial Public Offering represents a major milestone in the Company's development and I would like to thank all of our shareholders, both longstanding and new, our partners and our staff for their support and their contribution to this success."*

The offering price has been set at €11.70 per share. Total demand has reached approximately €64m. Overall, the number of shares issued reaches 4,273,504 allowing a share capital increase of €50m (including share premium). SuperSonic Imagine has granted the Joint Lead Managers and Joint Bookrunners acting in the name and on behalf of the banking syndicate an over-allotment option, exercisable from today until May 9th 2014 (included), on a maximum number of 641,025 new shares, or approximately €7.5m.

The new shares offered in the Offering will be allocated as follows (before exercise of the over-allotment option):

- Global Placement: 3,585,292 shares allocated (approximately €41.9m and 84% of the total number of shares issued);
- Open Price Offering (OPO): 688,212 shares allocated (approximately €8.1m and 16% of the total number of shares issued);
- In respect of the OPO, A1 and A2 orders will be fully allocated.

Based on a total of 15,610,880 shares to be admitted to trading and a value of €11.70 per share, total market capitalization of the Company stands at €182.6m.

The settlement/delivery of newly issued shares in the Open Price Offering and the Global Placement will occur on April 10th, 2014. From the 10th to the 14th of April 2014 (inclusive), the Company's shares will be traded in the form of undertakings to deliver shares (*promesses d'actions*) and in the form of ordinary shares, from April 15th, 2014. Shares are admitted to trading on Compartment B of the regulated market of Euronext in Paris under the ISIN code FR0010526814 and under the symbol SSI.

Several historical shareholders of the Company participated in the IPO through the subscription of a total amount of €15m.

Use of proceeds

The proceeds from the IPO are intended to provide the Group with additional financial resources in order to fund its ongoing operations (including its current working capital needs), in particular for the following purposes (presented in order of importance):

- the international commercial development of the Company, through reinforcing its direct sales network and promoting a worldwide distribution network;
- the continuation of the Company's strategy on innovation in order to (i) consolidate its technological lead (platform B) and (ii) expand the range of applications covered by Aixplorer®; and
- the establishment of a family of products covering several price segments, in particular portable ultrasound, which represents the fastest-growing part of market.

Timetable of the offering – upcoming dates

April 10th, 2014	<ul style="list-style-type: none"> ▪ Beginning of trading of the Company's shares on the regulated market of Euronext in Paris in the form of undertakings to deliver shares (<i>promesses d'actions</i>) (until April 14th, 2014 inclusive)
April 14th, 2014	<ul style="list-style-type: none"> ▪ Settlement/delivery of the Open Price Offering (OPO) and the Global Placement
April 15th, 2014	<ul style="list-style-type: none"> ▪ Beginning of trading of the Company's shares on the regulated market of Euronext in Paris
May 9th, 2014	<ul style="list-style-type: none"> ▪ Expiry date for the exercise of the Overallotment option ▪ End of the stabilization period, if any

Identification codes for SuperSonic Imagine shares

- **Company name** : « SuperSonic Imagine » (and « SuperSonic Imagine – promises » for the undertakings to deliver shares that will be tradable from April 10th to April 14th inclusive)
- **ISIN** : FR0010526814
- **Symbol** : SSI
- **Compartment** : Compartment B
- **Sector** : 4535 Medical Equipment (ICB classification)

Financial intermediaries



Global Coordinators, Joint Lead Managers and Joint Bookrunners



Co-Lead Managers



Company Advisor



Availability of the prospectus – Copies of the prospectus, which received a visa from the AMF on March 25th, 2014 under the number 14-093, composed of the *Document de Base* filed with the AMF on March 6th, 2014 under the number I. 14-006 and the *Note d'Opération* (including a summary of the prospectus), may be obtained free of charge and upon request from SuperSonic Imagine at Les Jardins de la Duranne – Bât. E – 510, rue René Descartes, 13857 Aix-en-Provence Cedex and from the internet websites of SuperSonic Imagine (www.supersonicimagine.fr) and the AMF (www.amf-france.org).

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN

Risk factors – SuperSonic Imagine draws the public's attention to chapter 4, "Risk factors", of the *Document de Base* registered with the AMF, and to chapter 2 "Risk factors related to the Offering" of the *Note d'Opération*.



About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer[®], with an UltraFast[™] platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer[®] is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave[™] Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer[®] on the main markets. As of December 31, 2013, SuperSonic Imagine has an installed base of 773 Aixplorer[®] ultrasound systems in over 50 countries. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital, NBGI and others.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.fr



SuperSonic Imagine

Michele Debain
Global Marketing Director
michele.debain@supersonicimagine.fr
Tel. +33 4 42 99 24 32 - +33 6 07 47 30 30

NewCap

Investor Relations
Pierre Laurent / Florent Alba
supersonicimagine@newcap.fr
Tel : +33 1 44 71 98 55

H&B Communication :

Media Relations
Florence Portejoie
f.portejoie@hbcommunication.fr
Tel : +33 1 58 18 32 58

Disclaimer

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for SUPERSONIC IMAGINE shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:

This press release does not constitute an offer to sell or any solicitation to purchase or subscribe for securities in the United States. The shares, or any other securities of SUPERSONIC IMAGINE, may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended, or exempt from registration. The shares of SUPERSONIC IMAGINE have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and SUPERSONIC IMAGINE does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular, by Directive 2010/73/EC of the European Parliament and the Council of November 24th, 2010 and as implemented in each member State of the European Economic Area (the "Prospectus Directive"). With respect to the member States of the European Economic Area which have transposed the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to in this press release requiring a publication by SUPERSONIC IMAGINE of a prospectus in any member State, other than France. As a result, the shares of SUPERSONIC IMAGINE may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been implemented by the relevant member State or in any other circumstances not requiring SUPERSONIC IMAGINE to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The prospectus registered with the Autorité des Marchés Financiers contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which SUPERSONIC IMAGINE operates.

Société Générale, acting as stabilising agent, or any institution acting on its behalf may, during a period of 30 days following the date on which the Offering Price is determined, i.e., according to the indicative timetable, from 9 April to 9 May 2014, effect transactions with a view to maintaining the market price of the SUPERSONIC IMAGINE shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation number 2273/03 of 22 December 2003. These activities are intended to support the market price of the SUPERSONIC IMAGINE shares and may affect the share price.